How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,145 results for

E/M Established Outpatient Visit

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. Preventing and Managing Infectious Diseases Among People who Inject Drugs in Ontario

to care for infectious diseases at all levels. Specifically, those who are homeless or marginally housed often have difficulty affording transportation to and from points of access for health and social services, lack the identification needed to access health and social services, and regularly move locations where they may not know how to access care, which may disrupt any trust or continuity in care that has been established with a previous provider. Finally, as noted earlier, those who are homeless

2019 McMaster Health Forum

82. A Case Management Tool for TB Prevention, Care and Control in the UK

month of medication (see Appendix 1: Form 3). Patient to be notified on TB surveillance system. One week Make contact with patient either by telephone or home visit (clinically assess patient and the environment and complete contact list within five working days). Visiting the patient in their own environment enhances the assessment of their needs and contact identifying. Two weeks Seen by case manager as an outpatient or in the community. One month Seen by case manager as an outpatient (...) clinical action 60 13. Simple guide to information sharing 61 ContentsROYAL COLLEGE OF NURSING 7 Glossary 62 References 65 Further reading 68A CASE MANAGEMENT TOOL FOR TB PREVENTION, CARE AND CONTROL IN THE UK 8 Purpose of this document This is a practical manual for any clinical or non-clinical professional involved in the case management of suspected and confirmed TB cases. It aims to: • promote standardisation of protocols and procedures • ensure accountability for delivery • establish clear

2019 Royal College of Nursing

83. Systematic Review - Relationship of Deployment-related Mild Traumatic Brain Injury to Posttraumatic Stress Disorder, Depressive Disorders, Substance Use Disorders, Suicidal Ideation, and Anxiety Disorders

of TBI to Psychiatric Conditions Evidence Synthesis Program i PREFACE The VA Evidence Synthesis Program (ESP) was established in 2007 to provide timely and accurate syntheses of targeted healthcare topics of importance to clinicians, managers, and policymakers as they work to improve the health and healthcare of Veterans. These reports help: · Develop clinical policies informed by evidence; · Implement effective services to improve patient outcomes and to support VA clinical practice guidelines (...) , Spoont M, Taylor B, MacDonald R, McKenzie L, Rosebush C, Wilt TJ. Relationship of Deployment-related Mild Traumatic Brain Injury to Posttraumatic Stress Disorder, Depressive Disorders, Substance Use Disorders, Suicidal Ideation, and Anxiety Disorders: A Systematic Review. Washington, DC: Evidence Synthesis Program, Health Services Research and Development Service, Office of Research and Development, Department of Veterans Affairs. VA ESP Project #09-009; 2019. Available at: https

2019 Veterans Affairs Evidence-based Synthesis Program Reports

84. Janus Kinase Inhibitors and Biosimilars for Rheumatoid Arthritis: Effectiveness and Value

, other benefits, and contextual considerations sections of the report. Varun M. Kumar developed the cost-effectiveness model and potential budget impact analysis and authored the corresponding sections of the report. Laura Cianciolo authored the section on coverage policies, managed the timeline and public process, and performed quality controls. Eric Borrelli authored the section on clinical guidelines. Pamela Bradt and Steven D. Pearson provided methodologic guidance on the clinical and economic (...) evaluations. We would like to thank Rick Chapman, Noemi Fluetsch, Foluso Agboola, David Rind, and Patty Synnott for their contributions to this report. We would also like to thank Jordan Amdahl, Rebecca Bornheimer, and Gerry Oster from Policy Analysis Inc. for their technical support with heRo3 throughout the course of this review. ICER Staff and Consultants Jeffrey A. Tice, MD Professor of Medicine University of California, San Francisco Varun M. Kumar, MBBS, MPH, MSc (Former) Associate Director

2020 California Technology Assessment Forum

85. Acute Treatments for Migraine

Director, Practice Based Research & Quality Improvement Division of General Internal Medicine Massachusetts General Hospital, Boston Foluso Agboola, MBBS, MPH Director, Evidence Synthesis Institute for Clinical and Economic Review Rick Chapman, PhD, MS Director of Health Economics Institute for Clinical and Economic Review David M. Rind, MD, MSc Chief Medical Officer Institute for Clinical and Economic Review Steven D. Pearson, MD, MSc President Institute for Clinical and Economic Review Daniel R (...) , and the resulting ICER reports do not necessarily represent the views of the UIC. DATE OF PUBLICATION: January 10, 2020 How to cite this document: Atlas S, Touchette D, Agboola F, Lee T, Chapman R, Pearson S D, Rind D M. Acute Treatments for Migraine: Effectiveness and Value. Institute for Clinical and Economic Review, January 8,2020. http://icer-review.org/material/acute-migraine-evidence-report/ Steven Atlas served as the lead author for the report. Foluso Agboola led the systematic review and authorship

2020 California Technology Assessment Forum

86. Society of Interventional Radiology Quality Improvement Standards on Percutaneous Ablation in Renal Cell Carcinoma Full Text available with Trip Pro

. Global cancer statistics. CA Cancer J Clin . 2011 ; 61 : 69–90 | | | 1 ). The incidence of RCC has gradually increased over the last several decades, which has been attributed to the growing use of and technologic advancements in cross-sectional imaging in the diagnosis of intra-abdominal pathologies ( x 2 Shinagare, A.B., Krajewski, K.M., Braschi-Amirfarzan, M., and Ramaiya, N.H. Advanced renal cell carcinoma: role of the radiologist in the era of precision medicine. Radiology . 2017 ; 284 : 333–351 (...) ). According to guidelines from the American Urology Association (AUA) and the National Comprehensive Cancer Network (NCCN), partial nephrectomy (PN) remains the standard of care for patients with noncentral, T1a (≤4.0 cm), or T1b tumors (4.1–7.0 cm) ( x 7 Campbell, S., Uzzo, R.G., Allaf, M.E. et al. renal mass and localized renal cancer: AUA guideline. J Urol . 2017 ; 198 : 520–529 | | | 7 , x 8 Motzer, R.J., Jonas, E., Agarwal, N. et al. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer

2020 Society of Interventional Radiology

87. Palliative Care for Adults

Annotationswww.icsi.org Institute for Clinical Systems Improvement 14 Palliative Care for Adults Sixth Edition /January 2020 Debility/Failure to Thrive • Greater than three chronic conditions in patient over 75 years old • Functional decline • Weight loss • Patient/family desire for low-yield therapy • Increasing frequency of outpatient visits, emergency department visits, hospitalizations Cancer • Uncontrolled symptoms due to cancer or treatment • Introduced at time of diagnosis – if disease likely incurable (...) Palliative Care for Adults Sixth Edition January 2020 www.icsi.org Copyright © 2020 by Institute for Clinical Systems Improvement 1 Health Care Guideline: Palliative Care for Adults Text in blue in this algorithm indicates a linked corresponding annotation. Does patient choose hospice, and is hospice available? Patient presents with new or established diagnosis of a serious illness Initiate palliative care discussion 1 Assess patient’s palliative care needs based on the speci?ed domains

2020 Institute for Clinical Systems Improvement

88. KDOQI Clinical Practice Guidelines for Nutrition in CKD

). 1.1.10 In adults with CKD post-transplant, it is reasonable to consider using underweight and overweight/obesity status (based on BMI) as a predictor of higher mortality (OPINION). BMI and Protein Energy Wasting 1.1.11 In adults with CKD 1-5D and post-transplant, BMI alone is not sufficient to establish a diagnosis of PEW unless the BMI is very low ( 25 kg/m 2 ), the authors found no association between BMI and mortality at 10 years. 20 However, in the remaining studies in which BMI was examined (...) - Oral, Enteral, and Parental Nutrition ……………………… ……………………………….. 103 4.2 Nutrition Supplementation - Dialysate………………………………………..…….…… 115 4.3 Long Chain Omega-3 Polyunsaturated Fatty Acids ………………………… 119 Guideline 5: Micronutrients.……………………………………………………….…………. 128 5.0 General Guidance ……………………………………………………………………….. 128 5.1 Folic acid (with and without other B Vitamins) ……..…………………………………… 132 5.2 Vitamin C ………………………………………………………………………………… 137 5.3 Vitamin D ………………………………………………………………………………… 142 5.4 Vitamin E

2020 National Kidney Foundation

89. Treatment of Patients with Schizophrenia

Treatment of Patients with Schizophrenia This guideline is undergoing copyediting and the final version is expected to be released summer 2020. THE AMERICAN PSYCHIATRIC ASSOCIATION PRACTICE GUIDELINE FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA Guideline Writing Group George A. Keepers, M.D. (Chair) Laura J. Fochtmann, M.D., M.B.I. (Vice-Chair; Methodologist) Joan M. Anzia, M.D. Sheldon Benjamin, M.D. Jeffrey M. Lyness, M.D. Ramin Mojtabai, M.D. Mark Servis, M.D. Art Walaszek, M.D. Peter (...) Buckley, M.D. Mark F. Lenzenweger, Ph.D. Alexander S. Young, M.D., M.S.H.S. Amanda Degenhardt, M.D. Systematic Review Group Laura J. Fochtmann, M.D., M.B.I. (Methodologist) Seung-Hee Hong Committee on Practice Guidelines Daniel J. Anzia, M.D. (Chair) R. Scott Benson, M.D. Thomas J. Craig, M.D. Catherine Crone, M.D. Annette L. Hanson, M.D. John M. Oldham, M.D. Carlos N. Pato, M.D., Ph.D. Michael J. Vergare, M.D. Joel Yager, M.D. (Consultant) Laura J. Fochtmann, M.D., M.B.I. (Consultant) APA Assembly

2020 American Psychiatric Association

90. Prenatal Care

, intrauterine growth restriction, and low birth weight. Established parameters for weight gain are based on pre- pregnancy body mass index (BMI). ACOG, IOM, and AAP recommend the following: Pre-pregnancy BMI (kg/m 2 ) Recommended Weight Gain 29 5.0-9.1 kg (11-20 lbs) Women with a BMI = 40 may benefit from lesser amount of weight gain or even weight loss during pregnancy. Behavioral counseling and dietary education have been shown to be beneficial for women with BMI 10,000 feet [3,000 meters]) is suggested (...) /90 mm/Hg for patients 60 - 85 years of age without diabetes. (HEDIS, BCBSM, BCN, CMS) BMI Screening: The percentage of members 18–74 years of age who had an outpatient visit and whose body mass index (BMI) was documented during the measurement year or the year prior to the measurement year. (HEDIS, BCBSM, BCN) Chlamydia Screening: The percentage of women 16–24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement year. (HEDIS

2020 University of Michigan Health System

91. Management of Cancer Medication-Related Infusion Reactions

the first day of administration. 8 Management of Cancer Medication-Related Infusion Reactions 7 Hypersensitivity reactions (HSRs) are a subset of IRs that occur at doses normally tolerated by patients and are not consistent with a known toxicity of the drug. 2 HSRs can be divided into subtypes as defined by Gell and Coombs, depending on the mechanism of reaction. • Type I reactions are those mediated by immunoglobulin E (IgE) antibodies, and include anaphylaxis, a type of systemic HSR that is severe (...) prophylaxis with extended infusion and/or pre-medications reduce IR rates. Current evidence suggests that pre-medications may reduce IR rates; however, the optimal pre- medication regimen has yet to be established. It may be reasonable to consider pre- medications (e.g. corticosteroids, H1-receptor antagonists ± H2-receptor antagonists) routinely in gynecological patients receiving carboplatin starting from the 7 th cycle, especially in patients at high risk of developing an IR. High risk factors include

2019 Cancer Care Ontario

92. Testosterone Testing - Protocol

and Determinants of Testosterone, Dihydrotestosterone, and Estradiol Levels Measured using Liquid Chromatography-Tandem Mass Spectrometry in a Population-Based Cohort of Older Men. J Clin Endocrinol Metab. 2012 Nov;97(11):4030–9. Kannenberg F, Fobker M, Schulte E, Pierściński G, Kelsch R, Zitzmann M, et al. The Simultaneous measurement of serum testosterone and 5α-dihydrotestosterone by gas chromatography–mass spectrometry (GC–MS). Clin Chim Acta. 2018 Jan;476:15–24. Locke J, Flannigan R, Etminan M, Tavokoli H (...) frequently receive prescriptions for testosterone replacement without first having a serum testosterone test to confirm low levels. This practice is not appropriate, as biochemical confirmation of a low for age serum total testosterone (or cBAT) is necessary to confirm the clinical impression of hypogonadism. In the absence of this biochemical confirmation, a re-visitation or verification of the original empiric diagnosis will be very difficult since prolonged androgen therapy will result in suppression

2019 Clinical Practice Guidelines and Protocols in British Columbia

93. Informing best practice in writing discharge summaries

details Y Sick note Y Support to relatives Y Religious/cultural concepts about disease/death Y Complimentary/alternativ e medicines y Pain relief Y Resuscitation status Y Optional nursing comments Y Reminder to bring documentation to next visit Y Psychosocial support Y Clinical trial involvement Y Excluded references 1. Amy J.H. Kind. Documentation of Mandated Discharge Summary. Components in Transitions from Acute to Subacute Care. 2012. Available online from: http://www.ncbi.nlm.nih.gov/books (...) associated with a discharge summary. There is currently no standardised template for a discharge summary used within Monash Health. Well-defined criteria for the quality of a discharge summary is lacking [1] . However, reviews of literature agree that good quality discharge summaries should avoid error, efficiently communicate information necessary for the ongoing care of a patient, and increase the quality of care of a patient [1-2] . Time pressure in hospitals, outpatient clinics and GP practices does

2019 Monash Health Evidence Reviews

94. Short message service (SMS) appointment reminders: A Rapid Review

Reminder Systems/ 20. exp "Appointments and Schedules"/ 21. exp Patient Compliance/ 22. Outpatients/ 23. Outpatient Clinics, Hospital/ut [Utilization] 24. Case Management/ 25. Office Visits/ 26. 8 or 9 or 10 or 11 or 12 or 13 or 14 27. 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 28. 26 and 27 29. exp animals/ not humans.sh. 30. 28 not 29 Study Selection Titles and abstracts identified were exported to EndNote X7 (Thompson, Reuters, Carlsbad, California, USA). Papers identified were (...) Preference and Adherence. 2017;11:141. 9. Downing SG, Cashman C, McNamee H, Penney D, Russell DB, Hellard ME. Increasing chlamydia test of re- infection rates using SMS reminders and incentives. Sexually Transmitted Infection. 2013 Feb 1;89(1):16-9. 10. Koshy E, Car J, Majeed A. Effectiveness of mobile-phone short message service (SMS) reminders for ophthalmology outpatient appointments: observational study. BMC Ophthalmology. 2008 Dec;8(1):9. 11. Strandbygaard U, Thomsen SF, Backer V. A daily SMS

2019 Monash Health Evidence Reviews

95. Handbook on designing and implementing an immunisation information system

28 4.1. High-level considerations 28 Fundamental differences between different European contexts exist in terms of legal regulations, IIS management, and user incentives. 29 4.1.1. A ‘top-down’ centralized approach 29 4.1.2. A ‘bottom-up’ approach 31 4.2. System-level considerations 33 4.2.1. Recording immunisation event data 33 4.2.2. Data elements 36 4.2.3. Establishing the denominator 43 4.2.4. Ensuring data quality 44 4.2.5. Storing data 46 4.2.6. User access 47 4.2.7. Linkage to other (...) . 2018: Proposed council recommendation on strengthened cooperation against vaccine-preventable diseases [18]. 1.5. Information technology, e-health, and IIS E-health in the EU Ehealth is a priority of the European Commission, and is therefore at the forefront of policies and directives related to widespread digitalisation of services in the EU [1] [19]. The definition and goals of eHealth, as per the EU Directorate General on Health, are given in Box 4. Box 4. Definition and goals of eHealth

2019 European Centre for Disease Prevention and Control - Technical Guidance

96. Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants within the EU/EEA

advisory group that was established to support the development of this guidance. The advisory group included the ad hoc scientific panel as well as experts and observers as follows: Karin Taus (Austria) Cliona M Cheallaigh (Ireland), Núria Serre Delcor (Spain), Sally Hargreaves (United Kingdom), Hilary Kirkbride (United Kingdom), Alison Crawshaw (United Kingdom), Isabel De La Mata (European Commission), Ludovica Banfi (European Union Agency for Fundamental Rights), Olga Gorbacheva and Jenna Iodice (...) the development of this guidance: Holger Schunemann, Elie Akl, Pablo Alonso-Coello, Peter Tugwell, Robin Christensen, Vivian Welch and Joerg Meerpohl. ECDC would like to acknowledge the support and guidance provided by members of the ECDC ad hoc scientific panel established to support the development of this guidance: Angel Kunchev (Bulgaria), Gabrielle Jones (France), Anna Kuehne (Germany), Andreas Gilsdorf (Germany), Agoritsa Baka (Greece), Lelia Thornton (Ireland), Francesco Castelli (Italy), Silvia

2019 European Centre for Disease Prevention and Control - Public Health Guidance

97. Public health guidance on HIV, hepatitis B and C testing in the EU/EEA

users to send emails, e-cards or text messages to inform partners anonymously. Post-exposure prophylaxis (PEP): Use of antiretroviral therapy following exposure to HIV infection to try to prevent establishment of infection. Prevalence: Prevalence measures proportion of individuals in defined population with specific disease (or specific characteristic) at certain point in time. High, intermediate and low prevalence rates may be defined for HCV, HBV and HIV to guide testing strategies after taking (...) or belong to local migrant communities known to have high prevalence or incidence of HBV/HCV/HIV. Opt-out testing: Testing modality where patients are informed they will be tested as part of routine care, but may decline testing by raising an objection to the test. Outpatient department: Hospital department that diagnoses and treats patients without requiring an overnight stay. Outreach: Type of health service that mobilises health workers to provide services to a population away from location where

2019 European Centre for Disease Prevention and Control - Public Health Guidance

98. France has delisted anti-dementia agents

France has delisted anti-dementia agents MED CHECK - TIP December 2018/ Vol.4 No.12 · Page 29 -The Informed Prescriber C N o 12 M ED HECK D e ce m b e r 2 0 1 8 Dying Cochrane: Could it be resuscitated? Herpes zoster subunit vaccine Shingrix: Baloxavir (Xofluza®) for Influenza: No Value No difference from Tamiflu in efficacy, and suppresses immunity Cochrane review on HPV vaccine should be revised: Due to missing trials, adjuvant toxicity, mortality and healthy user bias Editorial Dying (...) while three resigned in protest. The remaining one is Dr. Gøtzsche. Among the five appointed officers, two remained, and one resigned in protest followed by resignation of another officer who opposed the decision. The other one abstained from voting, but later resigned so that there would be less appointed members in the board. This means that six members were in favor of the expulsion while the other six, including Dr. Gøtzsche, were against it. By excluding Dr. Gøtzsche from the Editorial C M ED

2019 Med Check - The Informed Prescriber

99. Venous Thromboembolism (VTE)

Venous Thromboembolism (VTE) 1 Quality Department Guidelines for Clinical Care Ambulatory Venous Thromboembolism Guideline Team Team Leader Grant M Greenberg, MD, MA, MHSA Family Medicine Team Members Brian J Brophy, MD General Medicine Kirk A Frey, MD, PhD Nuclear Medicine James B Froehlich, MD, MPH Director, Anticoagulation Services R Van Harrison, PhD Medical Education Steven Kronick, MD Emergency Medicine Melissa A Miller, MD, MS Pulmonary & Critical Care Medicine Marc J Moote, MS, PA-C (...) Surgery David M Williams, MD Radiology Thomas W Wakefield, MD Vascular Surgery Initial Release June, 1998 Most Recent Major Update May, 2014 Interim/Minor Revision October, 2014 Ambulatory Care Guidelines Oversight Grant M Greenberg, MD, MA, MHSA R Van Harrison, PhD Literature search service Taubman Health Sciences Library For more information call: 734- 936-9771 © Regents of the University of Michigan These guidelines should not be construed as including all proper methods of care or excluding other

2020 University of Michigan Health System

100. Heart Failure - Systolic Dysfunction

Heart Failure - Systolic Dysfunction 1 Quality Department Guidelines for Clinical Care Ambulatory Heart Failure Guideline Team Team Leader William E Chavey, MD Family Medicine Team Members Barry E Bleske, PharmD Pharmacy R Van Harrison, PhD Medical Education Robert V Hogikyan, MD, MPH Geriatric Medicine Yeong Kwok, MD General Medicine John M Nicklas, MD Cardiology Consultant Todd M Koelling, MD Cardiology Initial Release August, 1999 Most Recent Major Update August, 2013 Interim/Minor Revision (...) Digoxin PRN e PRN e PRN e Ivabradine Selected patients f Selected patients f Non-pharmacologic Management Consider AICD/Bi-V pacemaker Selected patients g Yes Yes Yes HF Disease Management Yes Yes Referral to Advanced Heart Failure Program Yes Yes h Shading: = Recommended, = = Consider a One trial has demonstrated superiority of valsartan/sacubitril/ (ARNI) over enalapril in symptomatic patients. Given the lack of real world experience, either option is reasonable. ARNI should not be used

2020 University of Michigan Health System

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>